MSN-125 |
Catalog No.GC61096
One-Click Copy Product Info
|
MSN-125 is an inhibitor of Bax and Bak oligomerization, with an IC50 of 4μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1592908-16-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
MSN-125 is an inhibitor of Bax and Bak oligomerization, with an IC50 of 4μM[1]. Bax and Bak are key proteins in the apoptosis process[2]. Bax and Bak oligomerization increases the permeability of the mitochondrial outer membrane (MOMP), leads to the release of pro-apoptotic factors such as cytochrome c, thereby initiating the apoptosis program[3]. MSN-125 inhibits the oligomerization of Bax and Bak, prevents the increase of MOMP, and inhibits cell apoptosis[4]. MSN-125 is usually used to study the molecular mechanisms of apoptosis, especially in the fields of cancer and neuroprotection[5][6].
In vitro, MSN-125(5-10μM; 27h) inhibited cell death in HCT-116 or BMK cells treated with actinomycin D (ActD) or staurosporine (STS) and protected primary cortical neurons from glutamate excitotoxicity[1].
References:
[1] Niu X, Brahmbhatt H, Mergenthaler P, et al. A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes Neuroprotection. Cell Chem Biol. 2017;24(4):493-506.e5.
[2] Pena-Blanco A, Garcia-Saez AJ. Bax, Bak and beyond - mitochondrial performance in apoptosis. FEBS J. 2018;285(3):416-431.
[3] Yamazaki T, Galluzzi L. BAX and BAK dynamics control mitochondrial DNA release during apoptosis. Cell Death Differ. 2022;29(6):1296-1298.
[4] Jensen K, WuWong DJ, Wong S, Matsuyama M, Matsuyama S. Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax. Exp Biol Med (Maywood). 2019;244(8):621-629.
[5] Zhang Z, Hou L, Liu D, Luan S, Huang M, Zhao L. Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges. Acta Pharm Sin B. 2024;14(6):2378-2401.
[6] Spitz AZ, Gavathiotis E. Physiological and pharmacological modulation of BAX. Trends Pharmacol Sci. 2022;43(3):206-220.
| Cell experiment [1]: | |
|
Cell lines |
HCT-116 and BMK cells |
|
Preparation Method |
HCT-116 and BMK cells were seeded at a cell density of 3000 cells/well in a 96 well plate. Cells were plated in in DMEM containing 10% FBS and after adhering, cells were treated with MSN-125 (5-10μM) for 4 hours followed by addition of actinomycin D (ActD) or staurosporine (STS) for another 24 hours. Then cell death was analyzed by measuring lactate dehydrogenase release. |
|
Reaction Conditions |
5-10μM; 27h |
|
Applications |
MSN-125 inhibited cell death in HCT-116 or BMK cells treated with actinomycin D (ActD) or staurosporine (STS). |
|
References: |
|
| Cas No. | 1592908-16-1 | SDF | |
| Canonical SMILES | O=C(C1=CC=CC=C1)N[C@@H](CC2=CC=CC=C2)C(N(CC3=CC=C(C=C3)Br)[C@@H]4[C@H](OC5=CC(OCOCCOC)=CC=C45)CN)=O | ||
| Formula | C36H38BrN3O6 | M.Wt | 688.61 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4522 mL | 7.261 mL | 14.522 mL |
| 5 mM | 290.4 μL | 1.4522 mL | 2.9044 mL |
| 10 mM | 145.2 μL | 726.1 μL | 1.4522 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)